Abstract
Enfortumab vedotin for metastatic urothelial carcinoma: Comprehensive treatment outcomes and prognostic insights from a multicenter real-world study (YUSHIMA study)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have